BACKGROUND: The detection of a second tumor in patients with lung carcinoma raises the question whether this lesion is a metastasis or a second primary lung carcinoma. Patients cannot always be categorized satisfactorily according the criteria of multiple lung carcinoma proposed by Martini and Melamed. This may result in an inadequate treatment schedule in individual patients. Because p53 mutations can be used as clonal marker, the authors investigated whether p53 mutation analysis can differentiate between primary lung carcinomas and metastatic disease. METHODS: Sixty-four tumors in 31 patients with synchronous and metachronous lung tumors were investigated by p53 mutation analysis. RESULTS: In 21 patients, the tumors showed different p53 mutations, and therefore a definite diagnosis of multiple primary lung carcinoma was made. One of these patients did not meet the criteria of Martini and Melamed. In two other patients not matching these criteria, identical mutations were demonstrated in both tumors, indicating the presence of metastatic disease. In eight patients, analysis was not conclusive or possible. CONCLUSIONS: p53 mutation analysis can be a useful tool to confirm or rule out multiple primary lung carcinoma, and the results confirm the criteria of Martini and Melamed. However, in patients not meeting these criteria, the diagnosis of multiple lung carcinoma still has to be considered, and metastatic disease has to be ruled out. P53 mutation analysis can be helpful for this purpose. Copyright 2002 American Cancer Society.
BACKGROUND: The detection of a second tumor in patients with lung carcinoma raises the question whether this lesion is a metastasis or a second primary lung carcinoma. Patients cannot always be categorized satisfactorily according the criteria of multiple lung carcinoma proposed by Martini and Melamed. This may result in an inadequate treatment schedule in individual patients. Because p53 mutations can be used as clonal marker, the authors investigated whether p53 mutation analysis can differentiate between primary lung carcinomas and metastatic disease. METHODS: Sixty-four tumors in 31 patients with synchronous and metachronous lung tumors were investigated by p53 mutation analysis. RESULTS: In 21 patients, the tumors showed different p53 mutations, and therefore a definite diagnosis of multiple primary lung carcinoma was made. One of these patients did not meet the criteria of Martini and Melamed. In two other patients not matching these criteria, identical mutations were demonstrated in both tumors, indicating the presence of metastatic disease. In eight patients, analysis was not conclusive or possible. CONCLUSIONS:p53 mutation analysis can be a useful tool to confirm or rule out multiple primary lung carcinoma, and the results confirm the criteria of Martini and Melamed. However, in patients not meeting these criteria, the diagnosis of multiple lung carcinoma still has to be considered, and metastatic disease has to be ruled out. P53 mutation analysis can be helpful for this purpose. Copyright 2002 American Cancer Society.
Authors: Bernadette G Dijkman; Olga C J Schuurbiers; Dennis Vriens; Monika Looijen-Salamon; Johan Bussink; Johanna N H Timmer-Bonte; Miranda M Snoeren; Wim J G Oyen; Henricus F M van der Heijden; Lioe-Fee de Geus-Oei Journal: Eur J Nucl Med Mol Imaging Date: 2010-06-10 Impact factor: 9.236
Authors: William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz Journal: J Thorac Oncol Date: 2011-02 Impact factor: 15.609
Authors: Irene Orlow; Diana V Tommasi; Bradley Bloom; Irina Ostrovnaya; Javier Cotignola; Urvi Mujumdar; Klaus J Busam; Achim A Jungbluth; Richard A Scolyer; John F Thompson; Bruce K Armstrong; Marianne Berwick; Nancy E Thomas; Colin B Begg Journal: J Invest Dermatol Date: 2009-03-12 Impact factor: 8.551
Authors: Nicolas Girard; Irina Ostrovnaya; Christopher Lau; Bernard Park; Marc Ladanyi; David Finley; Charuhas Deshpande; Valerie Rusch; Irene Orlow; William D Travis; William Pao; Colin B Begg Journal: Clin Cancer Res Date: 2009-08-11 Impact factor: 12.531
Authors: Irene Orlow; Bernard J Park; Urvi Mujumdar; Himali Patel; Puiki Siu-Lau; Brian A Clas; Robert Downey; Raja Flores; Manjit Bains; Nabil Rizk; Gemma Dominguez; Jen Jani; Marianne Berwick; Colin B Begg; Mark G Kris; Valerie W Rusch Journal: J Clin Oncol Date: 2008-07-20 Impact factor: 44.544